What They Do
Tempus AI operates as a technology-driven precision medicine company that combines AI-powered diagnostics with vast multimodal healthcare data to improve cancer treatment decisions. They serve oncologists and healthcare systems by providing genomic testing services (like tumor profiling and liquid biopsies) while also licensing their proprietary datasets and AI models to pharmaceutical companies for drug development. Revenue comes from diagnostic testing fees and data licensing agreements.
Investment Thesis
**Explosive growth acceleration**: Core business revenue grew 33% in 2025 with oncology diagnostics showing 29% unit growth and the emerging MRD (minimal residual disease) business growing 56% quarter-over-quarter**Clear path to profitability**: Company guided to ~$65 million positive adjusted EBITDA for 2026 while maintaining 25% revenue growth, with gross margins of 69.6% providing strong operating leverage**Unique data moat**: Over 450 petabytes of connected multimodal healthcare data creating competitive advantages that management claims "other people have been unable to replicate," driving 126% net revenue retentionKey Risks
**Heavy losses narrowing slowly**: Despite strong revenue growth, company still projecting -$0.40 EPS for 2026, indicating significant cash burn continues**Competitive AI landscape**: Multiple players racing to develop healthcare AI solutions, with risk that larger tech companies or established diagnostics firms could erode Tempus's data advantagesGrowth Story
Tempus is experiencing accelerating growth across multiple business lines, with 2026 revenue guidance of $1.59 billion representing 25% growth. The company benefits from expanding oncology testing demand, breakthrough products like MRD liquid biopsies, and growing pharmaceutical partnerships for AI-powered drug development. Management sees significant runway with average selling prices targeting $2,200+ longer-term versus current ~$1,640.
Profitability Profile
The company maintains strong gross margins at 69.6% and is rapidly approaching profitability, guiding to positive adjusted EBITDA of ~$65 million in 2026. Operating leverage is evident as revenue scales faster than costs, with further margin expansion expected as higher-value tests gain adoption and average selling prices increase by $500+ over time.
Competitive Position
Tempus has built a differentiated position through its massive multimodal dataset (450+ petabytes) combined with AI capabilities that few competitors can match. While competing against established diagnostics companies and emerging AI players, their integrated platform of testing services plus data insights creates switching costs and network effects that strengthen over time.
Recent Momentum
The company delivered exceptional 2025 results, consistently beating revenue estimates by 1-6% across all quarters while achieving positive earnings surprises. Management expressed strong confidence with guidance that exceeded expectations, highlighting successful AI partnerships (including AstraZeneca deliverables) and infrastructure investments like a 500+ GB200 compute cluster for advanced model development.
What Wall Street Thinks
Analysts are increasingly focused on Tempus's AI competitive positioning and the scalability of newer products like MRD testing, which management suggested could be "20x higher" with unrestricted sales efforts. The consistent earnings beats and strong 2026 guidance appear to have strengthened confidence in the growth trajectory and path to profitability.
The Bottom Line
Tempus AI represents a rare combination of accelerating revenue growth (25%+ rates) with clear visibility to profitability in 2026, powered by a unique data asset that's becoming increasingly valuable as AI transforms healthcare.
